July 2009
With the recent opening of a 3,500-square-foot CLIA laboratory in California, the Amsterdam-based molecular diagnostic cancer testing manufacturer Agendia appears to be increasing its efforts to drive adoption of its MammaPrint test in the United States. The Amsterdam-based company also plans on doubling its sales force this year in the United States to increase this years MammaPrint volume, said Vice President of Sales and Marketing Daniel Forche, who started with the company last year.
Subscribers: click here for the full story
 Non-Subscribers: click here to subscribe
|
|
|
Archives
|
|